Plain-English translation of NCT06817161 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a procedure called transcutaneous auricular vagus nerve stimulation (taVNS), which uses mild electrical impulses applied to the outer ear to activate a nerve that may help reduce digestive problems. The study is designed for people with ovarian cancer who are starting their first round of chemotherapy. Researchers want to see whether this treatment can improve quality of life by reducing nausea, vomiting, and other digestive side effects caused by cancer treatment.
Chemotherapy can cause serious digestive side effects that make it hard to eat, feel comfortable, and enjoy daily life. This nerve stimulation approach activates the body's natural calming system, which may help ease these symptoms without adding more medications.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either receive real ear stimulation or placebo (sham) stimulation using an identical-looking device. Both groups use the device during the same visits and appointments at the cancer center while you are receiving your regular chemotherapy. The device is worn on the ear, and the study team will track how you are feeling, especially any digestive symptoms and your overall quality of life, throughout your cancer treatment.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France